Summary

Eligibility
for people ages 1 month to 79 years (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around
Principal Investigator
by Christopher Dvorak
Headshot of Christopher Dvorak
Christopher Dvorak

Description

Summary

Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults with refractory EBV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant.

Funding Source: FDA OOPD

Official Title

A Pilot Study in the Treatment of Refractory Epstein-Barr Virus (EBV) Infection With Related Donor EBV Cytotoxic T-Lymphocytes in Children, Adolescents and Young Adult Recipients

Keywords

Epstein-Barr Virus Infections, Primary Immune Deficiency Disorder, Infections, Communicable Diseases, Primary Immunodeficiency Diseases, Immunologic Deficiency Syndromes, cytotoxic t-lymphocytes, Refractory EBV

Eligibility

Locations

  • UCSF accepting new patients
    San Francisco California 94158 United States
  • Children's Hosptial Los Angeles accepting new patients
    Los Angeles California 90027 United States

Lead Scientist at UCSF

  • Christopher Dvorak
    My Research Interests are divided into 3 areas of focus: 1. Supportive Care (especially Invasive Fungal Infections) following Hematopoietic Stem Cell Transplantation 2. Transplantation for Severe Combined Immunodeficiency 3. Transplantation for Rare Leukemias (JMML and APL)

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
New York Medical College
ID
NCT03266653
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 20 study participants
Last Updated